Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy.

Consistent with the discovery cohort, MGAT5B-high patients tended to have shorter DFS and OS ( P = 0.095 and P = 0.11, respectively), although these did not reach statistical significance, possibly due to limited sample size (Fig. 2 K).

also in 111,027 other papers